Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of the drug velmanase alfa Lamzede in children under 3 years old who have Alpha-Mannosidosis, a rare genetic condition. The study aims to understand how velmanase alfa affects a specific disease marker called GlcNAcMan2 after one year of treatment and to observe how the childs body responds to the drug during therapy. This research collects data from real-world treatment experiences, including routine clinical tests and other observational studies. Participants are pediatric patients diagnosed with alpha-mannosidosis who have started treatment with velmanase alfa before turning three years old. They receive Lamzede as an intravenous enzyme replacement therapy at a dose of 1 mgkg once weekly. The study uses existing clinical data collected before and after treatment, focusing on samples taken prior to treatment initiation and after at least six weeks of therapy. During the study, parents or legal guardians provide test results from routine healthcare visits related to their childs general health and the administration of velmanase alfa. Researchers analyze these data to measure pharmacodynamic response over 52 weeks of treatment, focusing on changes in the disease marker GlcNAcMan2. The study continues until September 2029 and does not involve additional interventions beyond standard care and data collection.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an online educational program called Current Together After Cancer CTAC to see if it helps colorectal cancer survivors who had surgery receive follow-up care that matches current guidelines. This phase III trial focuses on patients with stage II or III colorectal cancer who have had their tumors surgically removed. The study aims to improve patients knowledge about surveillance, their confidence in managing follow-up care, and satisfaction with the involvement of a supporter in their care. Patients in the trial are randomly assigned to one of two groups. One group and their supporter get access to the CTAC intervention website, which contains educational content and interactive modules related to colorectal cancer surveillance. The other group and their supporter receive access to a general health education website. Participants may review their assigned website as often as they like for up to 16 months. During the study, participants will complete questionnaires at baseline, 3 months, and 16 months to assess knowledge, self-efficacy, cancer worry, preferences, and satisfaction with supporter engagement. Researchers will measure whether patients receive colorectal cancer surveillance aligned with guidelines at 16 months. The study also explores how supporters participation relates to patient outcomes. Participants may be contacted via email or phone for study activities and are encouraged to complete all scheduled assessments.
Actively Recruiting
Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.
Actively Recruiting
Researchers are studying the relationship between low muscle mass myopenia at the time of diagnosis and chemotherapy side effects in older adults newly diagnosed with advanced colorectal cancer. This observational study focuses on patients receiving 5-Fluorouracil 5-FU based chemotherapy, including combinations with oxaliplatin, irinotecan, or immunotherapy. The study also investigates how genetic differences may influence the link between myopenia and chemotherapy toxicity. Participants include older adults with newly diagnosed metastatic colorectal cancer or recent metastatic recurrence who are starting or planning to start first-line immunotherapy andor 5-FU chemotherapy. The study examines chemotherapy toxicities graded 3 to 5 during the first 6 months after beginning treatment and tracks overall survival for one year. No specific treatments are administered by the study, as it observes patients undergoing standard care. During the study, participants chemotherapy side effects are monitored and recorded, along with survival outcomes. Questionnaires are used to gather patient information, and eligibility requires the ability to understand English or Spanish. The study collects data for up to one year to evaluate how muscle mass and genetics affect chemotherapy outcomes in this population.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
This observational study follows individuals diagnosed with Rett syndrome who have mutations in the MECP2 gene. It gathers detailed information on the signs and symptoms of Rett syndrome as reported by expert clinicians and caregivers. The purpose is to use this data to develop consensus-based care guidelines and support the advancement of clinical trials and drug development for Rett syndrome. Participants are observed over a period of up to five years without receiving any experimental treatments. Data collection focuses on the natural history of the condition, capturing changes and progression as reported by medical experts and caregivers. There is no intervention or drug administration involved in this study. During the study, participants and their caregivers provide information on symptoms and health status. Researchers compile this data to understand the course of Rett syndrome better. The main outcome measured is the natural history over five years. Participants contribute information through routine clinical observations and caregiver reports throughout the study duration.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.
Actively Recruiting
Researchers are comparing two treatments for patients with 5 or more brain metastases stereotactic radiosurgery SRS and hippocampal-avoidant whole brain radiotherapy HA-WBRT combined with the drug memantine. This study aims to find out if SRS is better, the same, or worse than the usual treatment approach, which is whole brain radiation therapy alone. The study will assess how these treatments affect cancer control, overall survival, memory, quality of life, and cancer-related symptoms. Participants will be randomly assigned to receive either SRS, which delivers a high dose of radiation to specific small areas in the brain in a single session, or HA-WBRT plus memantine. HA-WBRT involves radiation to the whole brain while avoiding the hippocampus area to protect memory, given in 10 radiation fractions totaling 30Gy. Memantine is given starting at 5 mg and increased weekly to a target dose of 20 mg daily in divided doses. Treatment is provided as an outpatient procedure. During the study, participants will undergo regular assessments including MRI scans, neurocognitive testing, quality of life questionnaires, and blood tests to measure biomarkers. Researchers will monitor survival, brain cancer control, cognitive function, side effects, and treatment costs over 4.5 years. The study also includes collecting imaging and blood samples to understand treatment effects and brain changes. Participants are expected to be available for treatment, follow-up, and completing questionnaires throughout the study period.
Actively Recruiting
Researchers are evaluating two different radiation therapy schedules combined with standard chemotherapy drugs for treating patients with muscle invasive bladder cancer. This phase III trial aims to compare the effectiveness of ultra-hypofractionated radiation therapy, which delivers higher radiation doses over a shorter period, against the usual hypofractionated radiation therapy. The study seeks to show that the shorter radiation schedule is not worse by more than 10% in bladder-intact event-free survival at 3 years, while also assessing side effects, patient quality of life, and biomarkers related to disease recurrence. Participants are randomly assigned to one of two treatment groups. One group receives hypofractionated radiation therapy once daily, Monday through Friday, for 20 treatments alongside one of three chemotherapy regimens chosen by their doctor weekly cisplatin for 4 weeks gemcitabine given on several specified days or weekly for 4 weeks or mitomycin-C plus fluorouracil over two separate 5-day periods. The other group receives ultra-hypofractionated radiation therapy once daily, no more than twice a week, for 5 treatments with the same chemotherapy options. During the study, all patients undergo imaging scans such as CT, MRI, or PET, and may optionally provide blood and urine samples and biopsies during follow-up. Throughout participation, patients are monitored with scans and laboratory tests, and their symptoms and quality of life are tracked. Follow-up visits occur at week 16 after treatment, then every 3 months for 2 years, and every 6 months up to 5 years. The study measures bladder-intact event-free survival as the primary outcome, as well as urinary and bowel side effects, overall survival, and circulating tumor DNA as a biomarker. Optional sample collections and biopsies help researchers understand disease recurrence and response to therapy over the long term.
1-10 of 13
1